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Pediatric neuroblastoma: Long-survivor
A. Trin˜anes Perez, I. Nieto, V. Ochagavia, M. Medina Fana, R. Leiva Urbina, P. Willisch Santamaria,
M. Martinez Agra, V. Mun˜oz Garzon
Hospital do Meixoeiro, Servicio de Oncologia Radioterapica, Spain
Introduction. Neuroblastoma is an embryonal tumor of the sympathetic nervous system and his ﬁrst localization is the adrenal
gland. It is the most common solid tumor in childhood, 90% are diagnosed in the ﬁrst 5 years of life and generally in advanced
stages. Factors of poor prognosis are the abdominal location, the undifferentiated cells, more than one year old and ampliﬁcation
of N-myc gene (shown in 20% of cases). Tumors are sensitive to chemotherapy and radiotherapy. The estimated overall survival is
30-50% CASE: 7 year old girl with a VP shunt valve for hydrocephalus secondary to Chiari malformation type II and she presents
incontinence. At 2 years old is diagnosed with stage IV neuroblastoma, with N-myc ampliﬁed, adrenal primary and metastatic
involvement (lymphnode and bone), achieving complete remission after chemotherapy. Shewas treatedwith adrenalectomy and
autologous hematopoietic stem cell (bone marrow biopsy negative) followed by abdominal radiotherapy given 21Gy. At 5 years
to diagnosed she reports radiographic progression at mediastinal, retroperitoneal and bone. Receive 5 cycles of chemotherapy
with complete response, autologous hematopoietic progenitors and mediastinal radiotherapy given 21Gy by residual lesion. At
present, after 5 years of diagnosis, the disease is stable and without relapse.
Conclusions.We report a casewith poor initial prognosis, diagnosed at 2 years oldwith stage IV, located at abdominal, unresectable
with ampliﬁed N-myc gene, but with a multidisciplinary treatment the patient is asymptomatic and disease-free.
http://dx.doi.org/10.1016/j.rpor.2013.03.168
Pediatric tumors: Embryonal rhabdomyosarcoma GIII
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Six year old, female patient. Oncological history: Due to a gastrointestinal affectation and a severe general involvement, she visits
the ERwhere she is found to haveGI bleeding and a tumor in hypogastrium. She is urgently surgically intervened onApril 15, 1981,
and a mass 10 cm×8 cm in size is removed from anterior and posterior bladder, which at that moment has tore and is bleeding
profusely and has a cerebroid aspect; the pathological anatomy is consistent with a grade III embryonal rhabdomyosarcoma.
Upon this ﬁnding, chemotherapy is decided upon according to protocol (Vincrisul, actinomycin D and cyclophosphamide during
4 cycles). Later on, she is giving a RTE-2D treatment with Cobalt 60 by means of 4 ﬁelds, two laterals and a anterior and posterior
that encompass the entire volumen of the tumorectomy. Total dosage of 42Gy. Fractionation 5×150 cGy. Renal protección was
given at lateral and posterior ﬁelds, and hepathic protectionwith an anterior ﬁeld. The treatment lasted from10/06/81 to 22/07/81.
She tolerated it well. Evolution: Patient remained in follow ups by pediatrics. Following her diagnosis of primary hypogonadism,
secondary to pelvic radiotherapy, a substitute hormonal therapy with ethinilestradiol is started in 1992 but was suspended due
to lack of growth. She then, received growth hormone but discordant corporal proportions were observed. Reason for which she
was given microgynon, experimenting menarche that same year. At age 17, in 1993 during physical exploration, the patient is
found to have a grade I thelarche, grade II pubarche and grade III axilarche. From there on she has had a normal secondary sexual
development. Current status Toxicity outstanding: sterility. Currently this patient is symptom free (ILE 360 months).
http://dx.doi.org/10.1016/j.rpor.2013.03.169
Perivascular epithelioid cell tumor of the uterus (PECOMA) in a 21-year-old patient treated of meduloblastoma
in her childhood (at the age of 5)
J. Peinado Serrano, Y. Ruiz Ruiz, P. Cabrera Roldan, M. Ortiz Gordillo
Hospital Universitario Virgen del Rocio, Oncología Radioterápica, Spain
Introduction. Patient diagnosed at the age of 5 from a posterior fossa meduloblastoma. At the age of 21, new diagnosis of a PECOMA
uterus tumor. Long survival with low side effects.
General review. Medulloblastoma is the most frequent solid tumor (CNS) in children. Survival rate at ﬁve years is <50%. Common
treatment is based on surgery, radiation and chemotherapy.Wide range of side effects associatedwith treatment. Uterus PECOMA
is an infrequent (<1 case in 100,000) tumor that is related with the Tuberous Sclerosis (TS) spectrum of diseases. It is considered
as an unknown behavior malignant tumor. Recent data show relation between TS tumorigenic pathways and medulloblastoma.
Our case. Our patient suffer from Tuberous Sclerosis. She was diagnosed and treated at the age of 5 with complete surgical
resection followed by chemoradiation (30Gy to craniospinal axis and 50Gy to posterior fossa as a boost with a 2D planning) and
adyuvant chemotherapy. At the age of 21, in March 2012, in a gynecological review due to metrorrhagia, she was diagnosed from
a PECOMA uterus tumor. Simple hysterectomy was done. No adjuvant treatment associated. No evidence of recurrence of both
tumor at the present time. Carrying out a normal life.
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Conclusions. Treatment weapons against cancer have allowed us to see long time survivors despite some genetic disorders that
leads to cancer. Studying biomolecular tumorigenic pathways in this patients may lead us to better understand the basis of
cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.170
Radiation-induced atypical meningioma 19 years after treatment of medulloblastoma controlled with fraction-
ated stereotactic radiotherapy: A case report
C. Eito Valdovinos, M. Errasti Viader, G. Asín Felipe, M. Rico Osés, M. Domínguez Domínguez
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I present a case of meduloblastoma diagnosed en 1990, today a long term survivor for 22 years. The patient developed an atypical
meningioma 19 years after initial treatment and once again he is disease free following surgical resection and fractionated
stereotactic radiotherapy (FSRT). This is a 32 years old male patient. In 1990, at age nine, he was found to have a heterogeneously
enhancing posterior fossa mass with hydrocephalus. Gross total resection was performed and the tumor was consistent with a
classic medulloblastoma. Postoperative chemotherapy (VCR – CCNU) and 2D craniospinal radiation (34.2Gy/19 fr) with posterior
fossa 21.6Gy/12 fr boost was administered. The patient remained tumor free until November 2008, at which time he presented
with right sided weakness and numbness. MRI showed a supratentorial extra-axial mass located parasagittal into the left parietal
lobe, consistent with meningioma. Surgical resection of the tumor was undertaken on 01/22/10 and it was histopathologicaly
diagnosed as atypical meningioma WHO G2. Three months later MRI reveal a mass of 2.5 cm×2 cm×2.3 cm within the left
parietal lobe. FSRT was selected for reirradiation and 50.4Gy was delivered in 1.8Gy fractions to the gross tumor and surgical
bed PTV with 5 ﬁxed beams IMRT. He completed radiation treatments with only mild side effects but none of severe radiation
treatment late toxicities are presents today. I would note: (1) the radiation induced tumors risk after CNS irradiation; (2) the
treatment options for this condition with particular emphasis on curative reirradiation; (3) the patient status long time after
craniospinal irradiation and (4) the need of long-term follow-up for pediatric cancers survivors.
http://dx.doi.org/10.1016/j.rpor.2013.03.171
Sister’s Mary Joseph nodule at a patient followed for epidermoïde carcinoma of the cervix and literature review
S. Mansouri, A. Naim, S. Sahraoui, Z. Bouchbika, N. Benchekroun, H. Jouhadi, N. Tawﬁq, A. Benider
Radiotherapy Oncology Center of Casablanca Morroco, Spain
Sister’s Mary Joseph nodule is a rare lesion, term is used since 1949 to indicate an umbilical coetaneous metastasis of a cancer,
most often intra-abdominal principally gastric or ovarian. It represents 30% of umbilical tumours. In 90% of cases, it is about an
adenocarcinoma. The origin of the cancer is the stomach (26%), ovary (12%), colon (10%), pancreas (7%), other localizations can
be at the origin of this umbilical metastasis: appendix, small intestine. We report case of a 63-year-old patient, operated 3 years
previously for épidermoïde carcinoma type basaloide of cervix stage IB2, without ganglions invasion, followed by a concomitant
radio chemotherapy 45Gy and a vaginal irradiation 20Gy The patient presented an umbilical nodule of 5 cm, without other lesion
en abdomen or pelvis. The surgical complete resection of the nodule allowed of conﬁrmed by anatomopathological study, the
carcinoma basaloide. The diagnosis of Sister Marie Joseph’s nodule was retained. After a resection we have complete response
at 17 months, despite the poor prognosis which Sister Marie Joseph’s nodule attests.
http://dx.doi.org/10.1016/j.rpor.2013.03.173
Squamous cell carcinoma of cervix
M. Casado, S. Guardado, N. Gascón, C. Lechuga, M. Martín, M. Pérez-Escutia, J. Pérez-Regadera
Hospital 12 de Octubre, Spain
Woman, 62 years old PPH: smoker, 20 cigarettes per day Oncological History: in 1998, after being studied by metrorrhagia and
tenesmus of three months’ duration, was diagnosed ST IIIB cervical squamous cell carcinoma. Physical examination: KI: 100
gynecological exploration: exophytic cervical mass of at least 7 cm in diameter, that bleeds at touch. VT: the lump described is
felt at the left side of the vagina down to its mid third. RE: left parametrium involvement. Oncological treatment: RTE-2D over
PTV (pelvis), isocentric, 4 ﬁelds, (2AP+2LAT) with photons of 25 MV. Dosage: 50Gy, later on, overprint PTV2 (left parametrium),
2 ﬁelds, (PA and AP) Dosage: 16Gy. DT 66Gy (5×200 cGy). Cervical overprint with endocavitary radiotherapy by means of a No.
1 convergent colpostate, bearer of 3 sources of 137 CS. Dosage 15Gy to 0.5 cm of the vaginal cuff. Concurrent with Cisplatin x
6 cycles. Treatment ends on september1998. Complete clinical response. Evolution: December 2003: elevated SCC: 3.4, CYFRA:
1.9, on the thoracic abdominal pelvic TC a 3 cm right pulmonary hilar mass was noted and affected mediastinic adenopathies,
the rest was normal. February 2004: diagnostic mediastinoscopy. PA: metastasic lymph nodes squamous cell adenocarcinoma.
Rescue treatment: RTE 3D composed of PTV1 (hiliar mass+medistinum), isocentric, 4 ﬁelds (PA, AP, OBP and OBA), with 18 MV
photons, dosage: 45Gy, overprint PTV2 (hiliar tumoral mass), 2 ﬁelds (OBP and LD), 18 MV photons, dosage 14.4Gy, DT:59.4Gy
